GSK initiates Phase III trial of eltrombopag-azacitidine combination in MDS patients
GlaxoSmithKline (GSK) has initiated a Phase III trial, SUPPORT (TRC112121), of eltrombopag in patients with myelodysplastic syndromes (MDS), a type of cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 25, 2014 Category: Pharmaceuticals Source Type: news
GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™). (Source: GSK news)
Source: GSK news - June 25, 2014 Category: Pharmaceuticals Source Type: news
Myelodysplastic Syndrome - Mayo Clinic videos
What is Myelodysplastic Syndrome (MDS)? Raoul Tibes, M.D., Ph.D., hematologist at Mayo Clinic in Arizona, provides an overview of myelodysplastic syndrome (MDS) including the symptoms and diagnosis.Myelodysplastic Syndrome Treatment. Raoul Tibes, M.D., Ph.D. discusses various treatment options available for individuals diagnosed with myelodysplastic syndrome.
Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook. (Source: Clinical Cases and Images)
Source: Clinical Cases and Images - June 5, 2014 Category: Journals (General) Tags: Hematology Mayo Clinic Oncology Source Type: news
Cyclacel Pharmaceuticals Provides Update on Its Clinical Development Plan of Sapacitabine for Myelodysplastic Syndromes (MDS)
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - June 1, 2014 Category: Pharmaceuticals Source Type: news
Clinical Advisory: Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN 0901)
Source: National Cancer Institute, National Heart, Lung, and Blood Institute -
Related MedlinePlus Pages: Acute Myeloid Leukemia, Bone Marrow Transplantation, Myelodysplastic Syndromes (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 15, 2014 Category: Consumer Health News Source Type: news
Genetic tracking identifies cancer stem cells in human patients
The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer -- cancer stem cells. The international research team studied a group of patients with myelodysplastic syndromes -- a malignant blood condition which frequently develops into acute myeloid leukemia. The researchers say their findings offer conclusive evidence for the existence of cancer stem cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 15, 2014 Category: Science Source Type: news
Scientists Get Closer to the Stem Cells That May Drive Cancers
Researchers say a rare and unique tumor cell appears to help a form of blood cancer mutate and spread
Source: HealthDay
Related MedlinePlus Pages: Cancer, Myelodysplastic Syndromes, Stem Cells (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 15, 2014 Category: Consumer Health News Source Type: news
Genetic tracking identifies cancer stem cells in human patients
(University of Oxford) The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer -- cancer stem cells. The international research team, led by scientists at the University of Oxford and the Karolinska Institutet in Sweden, studied a group of patients with myelodysplastic syndromes -- a malignant blood condition which frequently develops into acute myeloid leukemia. The researchers say their findings offer conclusive evidence for the existence of cancer stem cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 15, 2014 Category: Cancer & Oncology Source Type: news
Kyowa HK Applies For Additional Indication Of NESP In Japan
Kyowa Hakko Kirin announced that is seeking approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) for additional indication of NESP Injection Plastic Syringe (NESP) for anemia with myelodysplastic syndrome. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 2, 2014 Category: Pharmaceuticals Source Type: news
Common blood cancer may be initiated by single mutation in bone cells
(Columbia University Medical Center) AML is a blood cancer, but for many patients the cancer may originate from an unusual source: a mutation in their bone cells. In a study published today in the online edition of Nature, researchers at Columbia University Medical Center found that a mutation in the bone cells called osteoblasts, which build new bone, causes AML in mice. The mutation was found in nearly 40 percent of patients with AML or myelodysplastic syndrome, a precursor condition, who were examined as part of the study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2014 Category: Cancer & Oncology Source Type: news
What scientific idea is ready for retirement?
Each year a forum for the world's most brilliant minds asks one question. This year's drew responses from such names as Richard Dawkins, Ian McEwan and Alan Alda. Here, edge.org founder John Brockman explains how the question came into being and we pick some of the best responsesEdge.org was launched in 1996 as the online version of "the Reality Club", an informal gathering of intellectuals who met from 1981 to 1996 in Chinese restaurants, artist lofts, investment banking firms, ballrooms, museums, living rooms and elsewhere. Though the venue is now in cyberspace, the spirit of the Reality Club lives on in the lively back-...
Source: Guardian Unlimited Science - January 12, 2014 Category: Science Authors: The Observer Tags: Astronomy Biology Mathematics Technology Physics Features Internet Animal behaviour The Observer Science Source Type: news
Mechanism discovered that controls the development of myelodysplastic syndromes
Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases.MDS primarily affects older individuals, with approximately 12,000 new cases diagnosed each year. In MDS, a person's blood is not able to make one or more types of healthy blood cells - red blood cells, white blood cells or platelets. Instead, the patient has a high number of immature stem cells that do not develop properly. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 24, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news
Moffitt researchers discover mechanism controlling the development of myelodysplastic
(H. Lee Moffitt Cancer Center & Research Institute) Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes, a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2013 Category: Global & Universal Source Type: news
Sunesis Pharma starts Phase I/II myelodysplastic syndrome study
US-based Sunesis Pharmaceuticals has started an investigator-sponsored Phase I/II trial of vosaroxin in combination with azacitidine for the treatment of patients with myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - December 12, 2013 Category: Pharmaceuticals Source Type: news
Access to transplants for MDS should not be limited by age
Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology."This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 10, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news
